Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial Results
Kindred Biosciences, Inc. (NASDAQ: KIN) will announce its fourth quarter and full year 2020 financial results on March 16, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kindred Biosciences, Inc. (NASDAQ: KIN) will announce its fourth quarter and full year 2020 financial results on March 16, 2021, after market close. A conference call will follow at 4:30 p.m. ET, accessible via toll-free number (855) 433-0927 or internationally at (484) 756-4262. The call will also be available as a live webcast. Kindred Biosciences focuses on developing safe and effective biologics for pets, utilizing targets that are already validated in humans. The company boasts a robust pipeline and advanced manufacturing capabilities.
Details
News Market Reaction – KIN
The recorded move for KIN in the trading session of this news was -4.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, March 8, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth quarter and full year 2020 financial results on March 16, 2021, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
Access the call by dialing toll-free (855) 433-0927 from the U.S. or (484) 756-4262 internationally, and using conference ID 3989605.
The call will also be webcast live here, with a replay available at that link for 30 days.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, visit: www.kindredbio.com
Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-announce-fourth-quarter-and-full-year-2020-financial-results-301241668.html
SOURCE Kindred Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.